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Introduction
Insul in pen devices are generally perceived by patients as being more convenient, flexible, and socially acceptable methods for administering insulin compared with traditional vial and syringe systems. [1] [2] [3] [4] As a result, prefilled and disposable pens are now the predominant method for injecting insulin in many countries among patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Nevertheless, the use of the vial and syringe still prevails in countries such as Brazil, India, and the United States 5 due, in part, to the perceived cost of using insulin pens relative to the vial and syringe. This is despite evidence showing that the overall treatment costs incurred by patients using insulin pens are lower than in those who use the vial and syringe, as a consequence of the lower rate of hypoglycemia associated with insulin pen use 3, 6 and the higher rates of adherence to treatment that are achieved with insulin pens. 7 In addition to the perceived convenience, flexibility, and social acceptability, insulin pens are able to accurately administer the required doses of insulin, as demonstrated in studies performed by trained research staff and by patients after receiving appropriate training for the device. [8] [9] [10] [11] [12] However, there are some additional features that could further improve these devices for patients. Practical aspects of insulin injection pen devices for people with diabetes include the ability to hear and feel clicks when dialing a dose, easy dialing and delivery, ease of performing safety tests, and overall ease of use and cartridge replacement in reusable pens. Specific features that may be attractive to pen users include insulin pens with higher maximum doses to reduce the need for splitdose injections (most pens have a dose limit of 60 U), reduced injection force and dial extension, and improved device differentiation, since most of the existing devices have little scope for differentiating between the different types of insulin to be injected, aside from the product label. Both reduced manual dexterity and visual impairments are common in people with diabetes, with up to 58% of people with diabetes having limited hand joint mobility 13 and 16 million people with diabetes in the United States predicted to have diabetic retinopathy by 2050. 14 In the United States, retinopathy accounts for approximately half of all cases of visual impairment among people with diabetes older than 50 years. 15 Visual impairment in people with diabetes is also frequently associated with other advanced age-related conditions, including macular degeneration, glaucoma, and cataracts. 16 
SoloSTAR
® is a novel insulin device approved for the administration of the long-acting insulin, insulin glargine (LANTUS ® ), or the rapid-acting insulin, insulin glulisine (Apidra ® ), all manufactured by sanofi-aventis for the treatment of T1DM or T2DM. SoloSTAR offers a higher maximum dose than many of the other insulin pens already available (80 U) and offers product differentiation by the use of different body colors for insulin glargine and insulin glulisine. This should be beneficial for patients with T1DM who are likely to use a basal and a bolus insulin as well as for the increasing number of patients with T2DM who are on basal-bolus regimens. Previous studies have demonstrated the dose accuracy, 10, 11 low injection force, 8 and patient preference for SoloSTAR versus other prefilled insulin pen devices. 17 The clinical acceptance of SoloSTAR with insulin glargine has been examined in an observational survey in Australia, 18 showing that health care professionals consider it easy to educate people with diabetes on the use of the pen and consider the pen easy for people with diabetes to use. However, the clinical acceptance and patient satisfaction with SoloSTAR using insulin glargine and/or insulin glulisine have been examined only in Australian patients with diabetes,
19 not yet in European or North American patients. Therefore, in this study, the authors investigated acceptance and patient satisfaction with SoloSTAR in Canada and 12 European countries.
Methods

Study Objectives
The objective of this study was to investigate patient satisfaction with SoloSTAR in people using insulin glargine and/or insulin glulisine in everyday clinical practice.
Study Design
This was a 6-8-week, multinational (Austria, Canada, Denmark, Greece, Hungary, Latvia, The Netherlands, Poland, Romania, Slovenia, Slovakia, Sweden, and the United Kingdom), multicenter (n = 645), open, prospective, observational product/device registry study performed between January 14, 2008, and April 4, 2009. The study was performed in accordance with the principles and all subsequent amendments of the declaration of Helsinki, in compliance with the guidelines for good epidemiological practice and in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. 20 All patients provided informed consent to participate in the study.
Study Population
Patients with T1DM or T2DM aged >18 years were enrolled. Subjects were eligible if they were current insulin users with prior disposable or reusable pen experience, or were insulin-naïve subjects on oral medications who were considered by their health care provider to be candidates for starting injectable insulin therapy. Exclusion criteria were current addiction to or abuse of alcohol and/or drugs, diagnosis of dementia, severe visual or dexterity impairment, or a mental condition rendering subjects unable to understand the nature, scope, and possible consequences of the study. Also excluded from the study were subjects who were considered to be uncooperative by the investigators and unlikely either to comply with the study or to reply honestly to the questionnaire or who had a concomitant disease or concomitant medication that may have interfered with their ability to participate in the study.
Study Protocol
The study consisted of two visits. At the initial registry visit (visit 1), patients were switched to, or started on, insulin therapy with LANTUS SoloSTAR for insulin glargine and/or Apidra SoloSTAR for insulin glulisine. For regulatory reasons, patients in Greece and Romania could be treated with SoloSTAR for no more than 15 days before the study to be considered eligible. All patients in Sweden were to be using SoloSTAR before inclusion. All treatment decisions were made in accordance with local clinical practice, and it was entirely at the physician's discretion whether to use insulin glargine, insulin glulisine, or both.
At visit 1, patients completed a questionnaire surveying their prior experience with insulin pens, if applicable, and their demographic and clinical characteristics were also assessed. After 6-8 weeks of SoloSTAR use as part of everyday clinical practice, patients completed a second questionnaire (visit 2) to document their experience and determine their acceptance of SoloSTAR. For patients who used an insulin pen before inclusion, acceptance of SoloSTAR was compared to the pen used before the study. In addition, the following information was collected: person who gave the insulin injection; use of other insulin pen before SoloSTAR; type of insulin currently used; number of injection devices currently used; start of SoloSTAR use the day patient received the supply; if patient did not start using SoloSTAR the day he or she received it, number of days after; whether patient was still using SoloSTAR; if patient was not still using SoloSTAR, number of days since he/she stopped; number of SoloSTAR pens used; disability or other restrictions; frequency of use of a new needle; frequency of safety test; brand of needles with SoloSTAR; face-to-face training on the use of SoloSTAR; confidence in the use of the pen after the training; and number of days to be confident in the use of SoloSTAR.
Treatment-emergent adverse events (TEAEs), possibly related TEAEs, and serious TEAEs were analyzed. Treatment-emergent adverse events are adverse events beginning between the first use of the SoloSTAR pen and the last use of SoloSTAR pen plus 7 days for SoloSTAR with insulin glargine and plus 2 days for SoloSTAR with insulin glulisine. For patients who were treated with SoloSTAR before inclusion in the study, TEAEs were counted from date of inclusion.
Study End Points
The primary end point was patient evaluation of the SoloSTAR pen. The following items (answered with excellent, good, acceptable, poor, or very poor) were described to evaluate the SoloSTAR pen: ease of selecting the dose; ease of correcting a misdialed dose; ease of reading the insulin dose; ease of feeling and hearing dialing clicks; force or effort needed to inject insulin; smoothness or gentleness of injection; ease of knowing that injection was completed or desired dose was delivered; ease of reading how much insulin remained in the cartridge; ease of differentiating the LANTUS SoloSTAR from the Apidra SoloSTAR, for patients using both; ease of learning how to use SoloSTAR; ease of use of SoloSTAR in general; overall assessment of SoloSTAR pen; plan to continue to use SoloSTAR (yes or no); and whether the patient would recommend SoloSTAR (yes or no).
Secondary end points were acceptance of individual pen features; insulin daily dose injected; number of daily injections; confidence in managing the pen or condition; occurrence of pen defects spontaneously reported by users; satisfaction with the previous pen, if appropriate, and comparison between SoloSTAR and the previous pen; and adverse events, including hypoglycemia (adverse events were recorded and coded using MedDRA version 8). 
Statistical Analysis
There was no formal sample size calculation for this observational study; however, the authors planned to recruit approximately 6900 patients across 645 centers distributed in 13 countries. The primary outcomes were evaluated using chi-squared tests for the overall population and for subgroups of patients according to age, diabetes type, prior history of using insulin and insulin pens, and whether the patient performed safety tests. Logistic regression was also performed to identify factors predicting satisfaction with SoloSTAR. Secondary outcomes and adverse events were assessed using appropriate summary statistics, with means ± standard deviation (SD) for continuous variables and n (%) for categorical variables. Factors recorded by questionnaire at visits 1 and 2 were analyzed by McNemar's test to evaluate change in these factors over the course of using the SoloSTAR pen.
Results
Baseline Characteristics
A total of 6542 patients were enrolled in this registry (6528 eligible; 14 excluded owing to missing age or that they did not have T1DM or T2DM). Of these, 6364 were included in the assessment of patient satisfaction and 6481 were included in the safety population (Figure 1 ): mean ± SD age of 54.3 ± 14.5 years, 48.7% were male, and 72.0% had T2DM. Overall, 164 patients were excluded from the patient satisfaction population for the following reasons: no insulin injections with SoloSTAR (n = 47), nonparticipation at baseline or follow-up (n = 82), or follow-up questionnaire was missing or completed more than 30 days after the last injection (n = 110; patients were allowed more than one reason for exclusion). The characteristics of the eligible patients are shown in Table 1 .
Prior Insulin Treatment
Most patients (77.1%) had previously received insulin (Table 1) , and the majority were using basal or rapidacting insulin, with similar proportions of patients using analog or human insulins; doses of insulin prior to the study are presented in Table 1 . The majority of patients ® 4 (Novo Nordisk; 9.3%). Of the 97.3% (n = 6305) of patients that used SoloSTAR with insulin glargine during the study, 29.2% (n = 1828) were using SoloSTAR with insulin glargine prior to the study. Of the 36% (n = 1929) that used SoloSTAR with insulin glulisine during the study, 23.7% (n = 454) were using SoloSTAR with insulin glulisine prior to the study. Before inclusion, 30.5% (n = 1975) of patients were using SoloSTAR with both insulin glargine and insulin glulisine, and 27.0% (n = 1753) used SoloSTAR with both insulin glargine and insulin glulisine during the study. A total of 655 patients (17.6%) were insulin-naïve prior to inclusion in this study, of which 81 patients were newly diagnosed with T1DM and initiated insulin therapy at the start of the study.
Insulin Therapy During the Study
During the study, most patients (97.3%, n = 6305) started SoloSTAR with insulin glargine with a mean daily dose of 26 ± 17 U [T1DM, n = 1749 (96.3%), 24 ± 12 U; T2DM, n = 4556 (97.7%), 27 ± 18 U]. In addition, 36% (n = 1929) of patients started SoloSTAR with insulin glulisine, with a mean daily dose of 31 ± 16 U [T1DM, n = 547 (38.1%), 29 ± 14 U; T2DM, n = 1382 (35.2%), 32 ± 17 U]. The median number of insulin glulisine doses per day was three (range 1-8 doses).
Evaluation of SoloSTAR
A total of 3569 patients completed the questionnaire documenting prior insulin and insulin pen use at baseline, and 6364 completed the follow-up questionnaire documenting their use of SoloSTAR during the study. Patients' perceptions of their previous pen (n = 3569) and of SoloSTAR (n = 6364) are summarized in Figure 2 . Previously used pen devices were generally perceived as excellent or good by similar proportions of participants for each of the factors recorded. However, the SoloSTAR pen was perceived extremely positively, as shown by the majority of patients who rated SoloSTAR as excellent across all eight factors. In particular, the ease of selecting the dose (prior pen, 38.1%; SoloSTAR, 76.3%) and the ease of correcting a misdialed dose (prior pen, 32%; SoloSTAR, 73.4%) were rated very highly for SoloSTAR by the total study population, compared with those documenting prior pen use. Less than 2% of patients rated SoloSTAR as poor or very poor for all eight factors, while 1.5-10.3% of the patients rated their previous device as poor or very poor. The final follow-up questionnaire also asked patients to directly compare SoloSTAR with their previously used pen. In total, 55.5% (2588/4660) rated SoloSTAR as much easier to use, 32.9 (1531) as easier, 9.9% (460) as the same, and 1.7% (79) as more difficult or much more difficult to use compared with the previously used device. In terms of ease of injecting the insulin dose, 54.7% (2538/4644) rated SoloSTAR as much easier, 29.8% (1386) as easier, 13.3% (618) as the same, and 2.2% (102) as more difficult or much more difficult to use. Of 1703 patients who compared ease of differentiation between SoloSTAR with insulin glargine and SoloSTAR with insulin glulisine, 72.7% of patients rated this factor as excellent, 22.2% as good, 3.8% as acceptable, 0.9% as poor, and 0.4% as very poor.
Overall, 87.7% (4092/4668) of patients stated that they preferred SoloSTAR to their previous pen, while 3.4% (160) preferred their previous pen and 8.9% (414) had no preference. The majority of patients were planning to continue to use SoloSTAR (98.2%; n = 6059) and would recommend SoloSTAR (98.8%; n = 6078). Additional data collected from the final follow-up questionnaire is reported in Table 2 .
Ease of Learning and Ease of Use
In the population of patients who were included in the assessment of patient satisfaction (n = 6364), the ease of learning and ease of use of SoloSTAR was rated as excellent (80.7% and 78.9%, respectively) or good (17.6% and 19%, respectively; Figure 3 ).
Overall Assessment of SoloSTAR
In the overall assessment of SoloSTAR (n = 6364), the device was rated as excellent by 75.8% of patients, good by 21.4%, acceptable by 2.0%, and poor or very poor by 0.7% (Figure 4) . Most patients planned to continue using SoloSTAR (98.2%) and would recommend SoloSTAR to others (98.8%). The overall assessment of SoloSTAR was comparable between age groups, type of diabetes, and prior use of insulin in patients with T2DM.
Safety
A total of 353 TEAEs were reported by 192 patients, of which 238 events in 105 patients were episodes of hypoglycemia ( Table 3) . Ten events corresponding to injection-site conditions were reported by 10 patients, including four episodes of injection site pain, three of injection site discomfort, and one each of cyst and injection site erythema. Thirty patients experienced a serious TEAE, of which three were considered by the investigator to be possibly related to insulin glargine treatment. One patient experienced moderate hypoglycemia due to an overdose of insulin glargine and was involved in a car accident. This occurred 4 days after the study start, and the patient recovered after 1 day. One patient experienced severe hypoglycemia due to an overdose of insulin glargine approximately 1 month after the study start. Recovery occurred on the same day. One patient experienced unconsciousness due to severe hypoglycemia following insulin glargine use. This occurred approximately 1 month after study start, and the patient recovered the same day.
Discussion
This European and Canadian study shows that SoloSTAR was well accepted in this large patient population. Overall, the results obtained in this study are consistent with those reported in a similar observational survey of Australian patients. 18 Indeed, most of the patients in both studies rated SoloSTAR as "excellent or good" for ease of use and learning, despite only 23% of patients in this study having not had prior insulin therapy, suggesting that, despite major changes in their therapy, patients accepted the new treatment and administration methods well. Furthermore, 15.5% of participants of the observational study had visual impairments and 16.3% had manual dexterity problems; however, compared with those who had no such impairments, they reported a similar level of satisfaction using SoloSTAR (mostly "satisfied" or "very satisfied"). 19 The majority of patients also preferred SoloSTAR versus their previous pen, rating SoloSTAR as easier to use, and planned to continue using SoloSTAR as part of their treatment regimen. In this study, insulin delivery with SoloSTAR was well tolerated, with relatively few TEAEs reported. Most adverse events were considered to be associated with the use of insulin glargine or insulin glulisine, rather than the use of the SoloSTAR device to inject the insulin. This observation, in combination with the accuracy of SoloSTAR previously demonstrated in simulated clinical settings, 9, 21, 22 should provide reassurance to patients and physicians alike that SoloSTAR could be appropriate for many patients, with low risk of patient errors in use.
The findings of this study must be weighed against a number of limitations. First, this study was performed in a nonrandomized patient population, and only half of the patients completed the questionnaire at visit 1, limiting the validity of the comparison between pens. However, because the patients completed the questionnaire regarding their prior pen at the initial visit, this should overcome any potential recall bias for this analysis. It must be acknowledged that patients with pen use experience were asked to compare SoloSTAR with their previous pen at visit 2, and this comparison may be subject to recall bias. However, the majority rated SoloSTAR as easier to use and inject and preferred SoloSTAR versus the previous pen. Second, a number with the SoloSTAR of patients had already used SoloSTAR with insulin glargine or insulin glulisine or both prior to visit 1, and these patients were included in the analysis of the initial questionnaire, which should be considered when interpreting comparisons between SoloSTAR and prior pens. Third, almost one-third of patients who previously used insulin pens did not complete the questionnaire at the initial visit, although they did complete the questionnaire at the follow-up visit. Accordingly, the perceptions of the previous device should not be directly compared with that of SoloSTAR, because these patients did not provide feedback on their previously used pen. Additionally, it is possible that not all adverse events were reported, possibly as a result of patient recall. Lastly, this study did not specifically evaluate the use of SoloSTAR in people with either severe visual or dexterity impairments. As these impairments are common among people with diabetes, future studies should assess the use of SoloSTAR in people with severe visual or dexterity impairments. Preliminary evidence suggests that visually impaired people are just as capable as those without impairment at self-administering insulin using pen devices.
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Conclusion
Taken together, the results of this study confirm those reported elsewhere 17, 19 that SoloSTAR is perceived by patients to be easy to use, particularly in comparison with previously used insulin pens, and is associated with high levels of user satisfaction among patients with diabetes worldwide. Future randomized controlled trials to compare the clinical utility of SoloSTAR versus the vial and syringe would be valuable, both in terms of assessing overall effects on patient satisfaction and glycemic control and in terms of risk of hypoglycemia and overall treatment costs.
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